Kaimi Biotech
Taizhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese diagnostics company developing innovative lateral flow assay platforms for point-of-care testing with proprietary sample collection technologies.
Substance Abuse Testing
Technology Platform
Unow™ lateral flow assay platform with innovative flocked pad for efficient saliva/urine collection, sample sufficiency indicator, and integrated reagent buffer system for reliable results.
Opportunities
Expansion into additional diagnostic areas beyond substance abuse testing using their versatile Unow™ platform, and potential partnerships with larger diagnostic companies for co-development of specialized tests.
Risk Factors
Intense competition in the lateral flow assay market from established global players, regulatory hurdles for international expansion, and dependence on limited current product portfolio.
Competitive Landscape
Competes with established lateral flow assay companies like Abbott, Siemens Healthineers, and Roche, but differentiates through proprietary sample collection technology and integrated buffer system designed for user-friendly point-of-care testing.